News News Details

Efung Glory | Riding the Cycle, Setting the Benchmark: Efung Capital Wins Dual Awards in LP CLUB's M

Date: 2026-07-27
Views: 1

Recently, the results of LP CLUB's 2026 Mid-Year Rankings were officially announced!

Efung Capital was honored on the prestigious China Equity Investment Outstanding Performance GP List, while Mr. Zhu Pai, CEO of Efung Capital, was named to the U45 China Equity Investment New Generation Leaders TOP50.

In 2026, China's equity investment industry stands at a critical watershed of a new cycle. With the full rollout of the "15th Five-Year Plan," the deepening implementation of new quality productive forces, and technological innovation elevated to a core national strategy, capital is no longer a mere financial numbers game—it has become the driving force behind industrial upgrading, the foundation of technological innovation, and the lifeblood of the real economy. From optimizing fundraising structures to sharpening investment focus, from diversifying exit channels to regularizing post-investment empowerment, the market is completing a profound value realignment within just half a year.

Themed "New Drivers of Strategic Investment," this ranking was hosted by LP CLUB, with Qichacha Technology Co., Ltd. serving as the strategic data support partner. Adhering to the principles of professionalism, neutrality, objectivity, and traceability, the selection process used half-year actual performance as the yardstick, strategic emerging and future industries as the main thread, and institutional execution capability as the core criterion. The goal was to identify benchmark players in the first half of 2026 that truly possess the resilience to navigate cycles, the commitment to deep industrial cultivation, and the ability to continuously create value—setting standards for the industry, charting direction for LPs, and energizing the industrial landscape.

Looking ahead, Efung Capital will continue to focus deeply on the biopharmaceutical sector, with a more forward-looking vision and more pragmatic post-investment empowerment, accompanying outstanding enterprises through market cycles and steadily contributing to the value reconstruction of China's equity investment industry and the in-depth advancement of technological innovation.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务